Seven Bridges Leads Public-Private Partnership to Develop New Data Ecosystem for NIH

November 6, 2017 Consortium will build cloud-based data resources, tools, and interoperable standards, giving researchers simultaneous access to biomedical datasets from across the National Institutes of Health CAMBRIDGE, Mass., November 06, 2017 – Seven Bridges, the leading biomedical data analysis company, today announced that it has been selected by the National Institutes of Health (NIH) to support... Read more

Zymo Research and VWR Team Up in Strategic Supplier Partnership

Zymo’s DNA Purification Products to be Sold through VWR’s North American Distribution Channels IRVINE, Calif., Oct. 31, 2017 /PRNewswire/ — The management at Zymo Research Corp. announced today a joint agreement with VWR to sell and distribute Zymo Research’s DNA purification, RNA extraction, microbiomic analysis, and epigenetics products throughout North America. VWR (NASDAQ:VWR), headquartered in Radnor, PA is the leading, global, independent provider of products, services,... Read more

Thermo Fisher Scientific Signs Oncology Companion Diagnostic Development Agreement with Blueprint Medicines

Thermo Fisher Scientific Signs Oncology Companion Diagnostic Development Agreement with Blueprint Medicines Agreement to expand Oncomine Dx Target Test with RET fusion markers to treat non-small cell lung cancer patients CARLSBAD, Calif., Oct. 31, 2017 /PRNewswire/ — As part of its ongoing commitment to increase the utility of next-generation sequencing (NGS) in the clinic, Thermo Fisher... Read more

Shimadzu Scientific Instruments, Cure Pharmaceutical Corp and CK Sciences Form a Strategic Alliance for R&D of Pharmaceutical Cannabis Products

Columbia, MD (October 25, 2017) — Shimadzu Scientific Instruments, the leading provider of cannabis testing instruments, announces it has signed a Memorandum of Understanding (MOU) with Cure Pharmaceutical Corp and CK Sciences. This collaborative agreement will focus on researching and developing safer pharmaceutical cannabis-based products and moving these products through clinical trials using FDA guidelines.... Read more

QIAGEN and ICMP launch next-generation DNA testing solutions for identifying missing persons

The Hague, 24 October 2017 – The International Commission on Missing Persons (ICMP) today announced the launch of a cutting-edge next-generation sequencing (NGS) workflow created in collaboration with QIAGEN N.V. for ICMP’s missing persons DNA identification laboratory in The Hague. The solution integrates QIAGEN’s GeneReader NGS System and spans all aspects of the DNA laboratory workflow, from... Read more

Fabric Genomics Partners to Improve Pediatric Care

October 19, 2017 06:00 AM Pacific Daylight Time ORLANDO, Fla.–(BUSINESS WIRE)–Fabric Genomics has partnered with Genomics England’s 100,000 Genomes Project, Rady Children’s Institute for Genomic Medicine (RCIGM), and The Utah Genome Project (UGP), to provide fast and accurate identification of pediatric disease-causing variants to improve the clinical care of children. Fabric Genomics’ Opal™ Clinical is the only genomic interpretation and reporting... Read more

Edico Genome And Fabric Genomics Develop Integrated Solution For Genomic Analysis With The Goal Of Improving Clinical Care

Industry Leaders Partner to Provide Streamlined Variant Data Analysis Solution ORLANDO, Fla., Oct. 19, 2017 /PRNewswire/ — Today at the American Society for Human Genetics (ASHG) Annual Meeting, Edico Genome and Fabric Genomics announced their collaboration to provide an integrated solution for secondary and tertiary analysis of next-generation sequencing data. Through this partnership, users can seamlessly utilize Edico Genome’s DRAGENTM Bio-IT platform with Fabric... Read more

BD Statement On European Commission Conditional Clearance Of Bard Acquisition

FRANKLIN LAKES, N.J., Oct. 18, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the European Commission for BD to acquire C.R. Bard (NYSE: BCR), contingent on BD divesting its soft tissue core needle biopsy product line: “We continue to make... Read more

Acquisition of The Omnicon Group, Inc.

18 October 2017 – Spectris plc (‘Spectris’) (LSE: SXS), the productivity-enhancing instrumentation and controls company, today announces that it has completed the acquisition of the privately-held US company The Omnicon Group, Inc. (‘Omnicon’) for an initial consideration of $29 million. Omnicon provides a range of services to help its customers analyse and improve product reliability... Read more